CHARLESTON, S.C.--(BUSINESS WIRE)--SCRA Technology Ventures’ SC Launch Portfolio Company FirstString Research has recently completed a multicenter, randomized clinical trial where a novel peptide has been found to heal chronic venous leg ulcers twice as quickly as the current standard of care. FirstString’s product, Granexin™ gel, which contains the peptide, ACT1, possesses anti-inflammatory and regenerative properties. The results of this Phase 2 study, investigating the efficacy and safety of this topical ACT1 formulation when combined with standard care in treatment of chronic venous leg ulcers, were recently published in the prestigious Journal of Investigative Dermatology. The study findings have been released and will be available in print in the upcoming issue.
Help employers find you! Check out all the jobs and post your resume.
